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Abstract: Implantable ventricular assist devices (VADs)
have proven efficient in advanced heart failure patients as a
bridge-to-transplant or destination therapy. However,
VAD usage often leads to infection, bleeding, and throm-
bosis, side effects attributable to the damage to blood
cells and plasma proteins. Measuring hemolysis alone does
not provide sufficient information to understand total
blood damage, and research exploring the impact of cur-
rently available pumps on a wider range of blood cell
types and plasma proteins such as von Willebrand factor
(vWF) is required to further our understanding of safer
pump design. The extracorporeal CentriMag (Thoratec
Corporation, Pleasanton, CA, USA) has a hemolysis
profile within published standards of normalized index of
hemolysis levels of less than 0.01 g/100 L at 100 mm Hg but
the effect on leukocytes, vWF multimers, and platelets is
unknown. Here, the CentriMag was tested using bovine
blood (n = 15) under constant hemodynamic conditions in
comparison with a static control for total blood cell
counts, hemolysis, leukocyte death, vWF multimers, micro-
particles, platelet activation, and apoptosis. The CentriMag
decreased the levels of healthy leukocytes (P < 0.006),
induced leukocyte microparticles (P < 10−5), and the level
of high molecular weight of vWF multimers was signifi-
cantly reduced in the CentriMag (P < 10−5) all compared
with the static treatment after 6 h in vitro testing. Despite
the leukocyte damage, microparticle formation, and
cleavage of vWF multimers, these results show that the
CentriMag is a hemocompatible pump which could be
used as a standard in blood damage assays to inform the
design of new implantable blood pumps. Key Words:
CentriMag centrifugal pump—Platelet activation—Cell-
derived microparticles—Hemolysis—von Willebrand
factor—Leukocyte damage—Apoptosis.
Implantable rotary left ventricular assist devices
(LVADs) have emerged as mainstream treatment
for severely symptomatic heart failure in selected
nontransplant eligible patients (1,2). Survival data
from INTERMACS suggest that LVAD outcomes
now rival transplantation particularly in patients with
ischemic cardiomyopathy (3). This has stimulated
interest in even smaller devices aimed at improving
quality of life and minimizing potentially life-
threatening complications. Pump thrombosis and
systemic thromboembolism persist as the major limi-
tation of this technology and has proven difficult to
predict from in vivo testing in sheep or calves (4).
Nonetheless, extensive preclinical testing is manda-
tory prior to clinical application of any new LVAD
(5). Hemocompatibility testing plays a major role in
this and as much as possible should be learnt from in
vitro work before animal implants. Shear stress
encountered by blood in transit through a rotary
pump can affect both cells and large proteins in the
plasma. Thus, blood testing requires more than
evaluation of hemolysis as platelets, leukocytes, and
plasma proteins all contribute to the propensity for
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infection, gastrointestinal (GI) bleeding, and throm-
bus formation (6–12). It is important to assess overall
damage by a new device against a baseline as early as
possible in the development process so that design
iterations can be made if required.
First-generation pulsatile pumps caused damage
to CD4+ lymphocytes, reducing both functionality
and cell numbers, resulting in an immunological
phenotype resembling that of patients suffering
from HIV infection (8). This decline in the CD4+/
CD8+ cell ratio occurred as early as 1 month after
implantation with the HeartMate VAD (7). A study
on patients implanted with either HeartMate II,
HeartWare, or PVAD (Thoratec Corporation, Plea-
santon, CA, USA) demonstrated that the HeartMate
II pump activated granulocytes. This was measured
as CD11b (Mac1)-positive CD15-expressing cells by
flow cytometry by postoperative day (POD) 14 com-
pared with the other pumps, and this increase
remained until POD 120 (11). Activated leukocytes
have also been demonstrated to form circulating
microparticles, measured using flow cytometry as
CD11b+ or CD62L+ 1.5 μM small events in a group
of patients implanted with various assisting devices
including HeartMate II, Thoratec VAD, Ventrassist,
Circulite, and one patient on extracorporeal mem-
brane oxygenation (ECMO) (10). The same study
also identified an increase in CD31+/CD61+ platelet
microparticles as a sign of platelet activation.
However, current temporary extracorporeal blood
pumps, such as the widely used CentriMag centrifu-
gal pump (CP) (Thoratec Corporation), often mani-
fest a lesser blood damage profile than implanted
LVADs because of lack of size constraints. This
allows for larger slower moving rotors which provide
lower shear stress. Combined with relatively low-cost
replaceable pump heads and convenient flow connec-
tors, this makes extracorporeal blood pumps a good
choice as a baseline control for incorporation into a
disposable test loop for in vitro hemocompatibility
testing. The CentriMag manifests very low hemolysis
levels (NIH of 0.0029 in vitro [13,14]), so we sought
to characterize the overall hemocompatibility profile
of this device in vitro with the intention of using this
pump as a benchmark control for development of a
new long-term rotary LVAD.
MATERIALS AND METHODS
Preparation of test blood
Blood was collected and prepared as described
previously (9). In brief, whole bovine blood was col-
lected into 14% citrate phosphate dextrose adenine
(CPDA-1) anticoagulant solution and antibiotics
(50 mg/L gentamycin and 10 mL/L antimycotic solu-
tion [Sigma Aldrich, Poole, UK]) (15,16). Hemato-
crit levels were adjusted to 30 ± 2% by dilution with
phosphate buffered saline (PBS) (Life Technologies
Ltd., Paisley, UK) and transferred into the test circuit
within 4 h after sample collection (15).
Device operation and specifications
CentriMag CP was tested using an in vitro testing
circuit under constant hemodynamic conditions in
accordance with ASTM Standards. The test param-
eters were controlled such that: the flow rate was
5 ± 0.25 L/min, measured using an ultrasonic flow
sensor (ME8-PXL, Transonic Systems Inc., Ithaca,
NY, USA); the differential pressure across the pump
was adjusted using a custom-made clamp to
100 ± 3 mm Hg, measured using pressure sensors
(PRESS-S-000, PendoTECH, Princeton, NJ, USA);
the volume of blood in the loop was 450 ± 45 mL; the
temperature of the loop was maintained at 37 ± 1°C by
the immersion of the blood reservoir and connecting
tubing in a temperature controlled water bath, with any
exposed tubing lagged to minimize temperature gradi-
ents. The test circuit was initially filled with PBS which
was circulated by the action of the pump for 20 min to
ensure all surfaces were wetted; PBS was drained prior
to blood transfusion. Care was taken during warming
(37 ± 1°C) of the blood to eliminate micro air bubbles.
Prior to the test being started, the loops were purged of
any air bubbles such that no air-blood interface existed.
Blood samples were taken at hourly intervals via a sam-
pling port in the blood reservoir. The first milliliter was
discarded followed by a second draw of 5 mL which
was used for the assays described below. A static
control sample as recommended by ASTM Standards
(15,16) was maintained at 37°C in a water bath
throughout the whole test and sampled in the same way
at the same time points.
Cell counts
The total numbers of leukocytes, platelets, and
erythrocytes were measured using the clinical
automatic hematology analyzer CELL-DYN Ruby
(Abbott Diagnostics, Berkshire, UK). The accuracy
of this for bovine blood was confirmed by analyzing a
subset of samples on an analyzer optimized for vet-
erinary purposes to confirm comparable results were
obtained (Langford Veterinary Services, University
of Bristol, UK).
Hemolysis assay
Three 1 mL aliquots of the hourly blood sam-
ples were centrifuged at 4200 × g for 7 min. Plasma
supernatant (100 μL) was transferred from each
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aliquot into three cuvettes (Thermo Scientific,
Loughborough, UK) and diluted with 1 mL 0.1%
Na2CO3 solution. The absorbance was measured
using a UV/visible spectrophotometer (6700 Series,
Jenway, Essex, UK) at three wavelengths: 380, 415,
and 450 nm; the plasma-free hemoglobin (pfHb) and
normalized index of hemolysis (NIH) were calcu-
lated as described by Eqs. 1 and 2, respectively (17).
pfHb A A A
Vol
Vol
= − −( )
×
1 672 0 836 0 836415 450 380
2 3
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where:
NIH: normalized index of hemolysis (g/100 L)
ΔpfHb: increase of plasma-free hemoglobin concen-
tration (g/L) over the sampling time interval
V: circuit volume (L)
Q: flow rate (L/min)
Ht: hematocrit (%)
T: sampling time (min)
Leukocyte death assay
Hourly blood samples (20 μL) were stained with
1 μL CD45-PE, clone 1.11.32, mouse IgG1 (Thermo
Scientific) for 30 min on ice in the dark (n = 7). The
red blood cells were lysed by adding 1 mL ammo-
nium chloride (Stem Cell Technologies, Grenoble,
France), followed by vortexing and 10 min incuba-
tion on ice in the dark. The cells were pelleted at
515 × g, 7 min, 5°C, and washed once with 2 mL
FACS buffer (PBS, Life Technologies Ltd.; 0.2%
bovine serum albumin, Sigma Aldrich; and 0.05%
sodium azide). Cells were resuspended in 100 μL
FACS buffer and stained with 2 μL 7AAD solution
(eBioscience, Hatfield, UK) at room temperature in
the dark for at least 15 min before acquisition. Anti-
body capture beads (Life Technologies Ltd.) were
used as single-stained compensation controls for
CD45-PE. As a positive control for 7AAD staining
of dead cells, 1 mL peripheral blood was treated with
3 μM Staurosporin solution (Sigma Aldrich) at room
temperature for at least 4 h prior to staining with
CD45-PE and 7AAD. Untreated blood single-
stained with CD45-PE was used as a negative control
in the 7AAD gate (see Figure 3). Samples were
acquired and analyzed using BD FACSAria I with
FACSDiva 6.1.3 software (BD Bioscience, Oxford,
UK) and 10 000 leukocytes or beads were recorded
uncompensated using the following filter configura-
tion: AnnexinV-eFluor450 = 405 nm laser and 450/40
filter, 7AAD = 488 nm laser and 695/40 filter, and all
PE-conjugated antibodies = 488 nm laser, 585/42
filter. FCS files were exported and analyzed in Kaluza
1.2 (Beckman Coulter, London, UK) using automatic
compensation. All events were displayed on a density
dot plot with forward scatter (FSC) against side
scatter (SSC), both on logarithmic axes. The leuko-
cytes were gated and displayed on a contour density
dot plot with 7AAD against CD45-PE, both on
logicle axes. The healthy cell gate was set using the
Staurosporin-treated control to just outside the main
contour of the healthy 7AAD-negative population
(Supporting Information Fig. S1). Any events to the
right of this border were considered 7AAD-positive
necrotic leukocytes. Fragmented white blood cells
(leukocyte microparticles; MPs) still display CD45
but no longer contain DNA and because of their
reduced size and complexity, and therefore lower
SSC, end up below the healthy leukocytes on an SSC
axis in the gate designated MP.
Platelet activation assay
A 20 μL aliquot of the hourly blood samples, along
with a positive control of blood treated with 4 μM
phorbol 12-myristate 13-acetate (PMA) for 60 min at
room temperature with gentle agitation, were stained
individually with 5 μL of BAQ125 (1.0 mg/mL, binds
activated bovine platelets but antigen still unknown
[18,19]) or CAPP2a (1.0 mg/dL, an anti-ruminant
CD41/61 antibody [20]) (both from Monoclonal Anti-
body Center, Washington State University), diluted
1:50 with FACS buffer, and were left to incubate on
ice for 30 min. Cells were washed once with FACS
buffer and then stained with 5 μL of 1.0 mg/dL
R-phycoerythrin F(ab′)2 fragment of goat anti-mouse
IgG (H + L) (Life Technologies Ltd.) diluted 1:20 with
FACS buffer and incubated in the dark on ice for
20 min. The red blood cells were lysed with 2 mL BD
FACS Lysing Solution (BD Bioscience) according to
the manufacturer’s instructions. Cells were washed
once with FACS buffer and fixed with 200 μL BD Sta-
bilizing Fixative (BD Bioscience) and stored at 4°C
overnight prior to acquisition using the instrument
set-up described above.
All events were displayed in the FSC versus SSC
graph on logarithmic scale. The platelet population was
gated to include both platelets in a resting and activated
state using the unstimulated control and the PMA-
stimulated sample as guidance (Supporting Informa-
tion Fig. S2); 10 000 events within this gate were
recorded. BAQ125 and CAPP2a are expressed on
resting inactivated platelets and decreased with platelet
activation. Markers were drawn on BAQ125 and
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CAPP2a histograms to measure the percentage of
negative events, and therefore percentage of activated
platelets (Supporting Information Fig. S2B and C).
Platelet apoptosis assay
A 20 μL aliquot of the hourly blood sample, as well
as the PMA-treated positive control, were stained with
2 μL of Annexin V-eFluor450 (eBioscience) (n = 3), on
ice in the dark for 15 min. Red blood cells were lysed
with 2 mL BD FACS Lysing Solution (BD Bioscience).
Cells were washed once with Annexin V binding buffer
(eBioscience) and fixed with 200 μL BD Stabilizing
Fixative (BD Bioscience) and stored at 4°C overnight
prior to acquisition using the instrument set-up
described above. Gating was carried out as above and
the platelet activation was displayed on a separate
Annexin V-histogram (Supporting Information
Fig. S2D). Annexin V positive events were gated to
measure the percentage of apoptotic platelets.
High molecular weight (HMW) von Willebrand
factor (vWF) degradation
Platelet-rich plasma (PRP) was prepared by cen-
trifuging hourly blood samples for 7 min at 4200 × g
at room temperature. Platelet-poor plasma (PPP)
was prepared by further centrifuging PRP for 5 min
at 13 000 × g at room temperature. The PPP was
extracted and analyzed using an automated hema-
tology analyzer CELL-DYN Ruby (Abbott Diagnos-
tics, Abbott Park, IL, USA) to ensure that the plasma
was void of blood cells. PPP was used instead of
whole blood to ensure that any potential effect of
shear on vWF was not a result of cellular inter-
actions. PPP was subjected to electrophoresis on
high gelling temperature agarose (0.6% agarose,
w/v, Sea Kem, FMC Bioproducts, Rockland, ME,
USA) in a horizontal gel apparatus (81-2325, Galileo
Bioscience, Cambridge, MA, USA) at 4°C. Electro-
phoresis was performed at 30 mA (after 30 min,
the current was increased to 50 mA until the dye
front had migrated 10–12 cm from the origin; total
run time was roughly 6 h). vWF multimers separated
on agarose gel were transferred to polyviny-
lidene difluoride 0.45 μM membrane (IPVH304F0,
Immobilon-P, Millipore Corporation, Billerica, MA,
USA) for 15–17 h at 70 mA in the electroblotting
tank (91-2020-TB, Galileo Bioscience). Detection
using anti-human vWF primary (ab6994, Abcam,
Cambridge, UK) and horseradish peroxidise
(HRP)-conjugated secondary (ab6721, Abcam) anti-
bodies, and chemiluminescence substrate (170-5060,
Bio-Rad, Hercules, CA, USA) was performed as
described by Krizek et al. (38). Pump-induced
changes in the size distribution of plasma vWF multi-
mers were studied by densitometric scanning initi-
ated from the origin (Quantity One software v4.6.8,
BioRad, Hertfordshire, UK). The loss of HMW vWF
multimers was quantified by the rate of change in the
gradient of HMW vWF.
Statistical analysis
Averages and standard deviations were calculated
for each assay. Due to multiple measurements taken
from each subject (both at the same time point to
compare CentriMag with static, and at the six different
time points), a set of repeated measures analysis of
variance (using the R statistical environment, v 3.0.2 [R
Core Team, Vienna, Austria], and RStudio v 0.97.551
[RStudio, Boston, MA, USA]) were applied. One
analysis of variance (ANOVA) was performed each for
the healthy, necrotic, and leukocyte MP analysis in the
blood samples. In each case the different subjects were
treated as a random effect, and the time points and
CentriMag/static as a fixed effect. While the three
ANOVAs are not independent (as the sum of the
events in the three flow cytometry gates will be 100%),
analyzing all separately aids the interpretation.
RESULTS
Cell counts
There was no change in the concentration of leu-
kocytes, erythrocytes, or platelets throughout the 6 h
testing period in the CentriMag or the static control
(see Fig. 1).
Hemolysis
Hemolysis was evident in both the pumped sam-
ple and in the static control (n = 15). There was a
steady increase in pfHb every hour with a statis-
tically significant difference between hours 0 and 6
for both CentriMag (P = 0.016) and static control
(P ≤ 0.001) (see Fig. 2). When comparing the 6 h
samples, there was no significant difference between
the CentriMag and the static control (P = 0.487),
indicating that the CentriMag causes minimal hemo-
lysis. NIH for the CentriMag was 0.0011 ± 0.0005 g/
100 L (n = 15; x ± SD).
Leukocyte death
The percentage of healthy leukocytes (i.e., 7AAD
negative and not microparticles) was significantly
reduced in the CentriMag compared with the static
control (P < 0.006). The effect of time was highly
significant (P < 0.001), with the difference between
the groups emerging at about 3 h and increasing
throughout the test (Fig. 3). Leukocyte MPs also
show a highly significant difference between the
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CentriMag and the static control (P < 10−5) but in the
opposing direction; the CentriMag results in a signifi-
cant increase, and the difference increases over time
(P < 0.003, Fig. 3). There was no difference between
CentriMag and static samples in terms of necrotic
(7AAD-positive) leukocytes. However, there was a
significant effect of time (P < 0.02, Fig. 3), with a
general small increase in both the CentriMag and the
static control.
Platelet activation and apoptosis
There was no significant difference between
CentriMag and the static control for platelet activa-
tion or apoptosis (P ≥ 0.9) (n = 7; Fig. 4).
HMW vWF degradation
The level of HMW vWF multimers was reduced
significantly in the CentriMag compared with the
static treatment (P < 10−5). The time effect was also
significant (P < 0.02). The difference between the
groups appeared at about 2–3 h and continued to
increase over the time period (Fig. 5).
DISCUSSION
The CentriMag temporary centrifugal VAD has
proven safety and clinical effectiveness in left and/or
right ventricular and ECMO support for long-term
use periods exceeding 300 days (22). Pump-related
hemolysis and adverse event rates are consistently
low, with outcomes depending predominantly upon
patient status rather than VAD complications. As
such, we chose to evaluate the CentriMag centrifugal
pump as a control device against which new VADs in
development can be tested. Our comprehensive in
vitro baseline assessment using bovine-citrated blood
confirms the low blood damage profile of CentriMag
as experienced in clinical practice. However, there
were significant differences in the total blood damage
profile of circulating blood driven by CentriMag and
static blood during the 6 h in vitro testing using a
broader range of assays. This includes a decrease in
healthy leukocytes, an increase in leukocyte frag-
mentation generating CD45+ microparticles, and a
reduction in HMW vWF multimers. The effects
became apparent around the 3 h mark and steadily
increased over time.
Patients with VADs have shown increased plate-
let, leukocyte, and endothelial MPs compared with
healthy controls. The MPs have been suggested to be
involved in thrombus formation, through binding
of platelets to activated endothelium and through
CentriMag
Stac
CentriMag
Stac
FIG. 1. CentriMag’s effect on blood cell levels. Whole bovine
blood diluted to hematocrit of 30 ± 2% with PBS and pumped for
6 h through a circuit by the CentriMag and compared with a static
control kept in a 37°C water bath. Total leukocytes, platelets, and
erythrocytes blood counts obtained by the CELL-DYN Ruby auto-
matic hematology analyzer plotted against time (n = 6–7, x ± SD).
There is no difference between CentriMag and static blood in
terms of blood cell levels.
FIG. 2. Hemolysis evaluation. Comparison of changes in plasma-
free hemoglobin (ΔpfHb) between the CentriMag temporary
mechanical circulatory support device and the static control
(n = 15). There was no significant difference between CentriMag
and static at hour 6 (P = 0.487), indicating that the CentriMag does
not cause high-level hemolysis. NIH for the CentriMag was
0.0011 ± 0.0005 g/100 L (n = 15; x ± SD).
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activation of the intrinsic coagulation pathway via
Factor XII exposure to negatively charged mem-
brane particles (10,23,24). Shear stress has been sug-
gested to mechanistically underpin MP release as
demonstrated by increased platelet-derived MPs
(PMPs) in patients implanted with prosthetic heart
valves who typically experience high levels of shear,
and whose elevated PMPs are the suspected cause of
cerebrovascular events. Therefore, it is of impor-
tance to measure the MP-levels caused by VADs in
vitro, to ensure new designs are made with minimal
shear and are as safe as possible.
GI bleeding is one complication associated with
the placement of a VAD, with rates as high as 65%
within the first year after VAD placement (21,25).
The mechanism underlying this problem in patients
on long-term continuous flow mechanical support is
not well understood (12,21,26–33). This cannot be
explained by the anticoagulation regimen alone, but
may be symptomatic of acquired von Willebrand
syndrome. This disease can be explained partially by
shear stress, as those suffering from aortic valve
stenosis and those implanted with axial flow VADs
both experience high shear and have reported bleed-
ing and loss of HMW vWF multimers (34,35). Thus,
comparing the degradation of vWF in VADs pro-
vides important feedback to device developers about
shear stress levels.
Over a 6 h period in the recirculating loop,
hemolysis and platelet damage remained low. Spe-
cifically, there was no difference between CentriMag
and static samples in relation to necrotic 7AAD+
leukocytes, nor significant differences in platelet acti-
vation or apoptosis. Both antibody studies showed
that background platelet activation occurs through-
out the testing period, but this did not differ to the
static control at 6 h. The Annexin V platelet apopto-
sis assay also indicates a low blood damage profile.
We intend to confirm these findings using human
blood as it is known that bovine platelets are less
reactive than human platelets in response to shear
stress (36,37). Our laboratory has previously carried
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FIG. 3. Leukocyte damage measured by
flow cytometry. Whole bovine blood tested
in the CentriMag (top row) versus static
control (middle row) at 6 h. Leukocytes
gate used to record 10 000 events.
Ungated events displayed on CD45-PE
versus SSC density plot and CD45+
events gated. CD45+ events displayed
on 7AAD versus SSC density plot and
healthy (7AAD-high SSC), necrotic
(7AAD+), and microparticles (MPs; 7AAD-
low SSC) events recorded for each
sample. CentriMag caused a significant
decrease in relative healthy events
(bottom left) (P < 0.006) and significant
increase in relative MP events after 3 h
(P < 10−5), indicating that leukocytes are
fragmented during the pumping process.
* Significant difference between Centri-
Mag and static control.
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out hemolysis and leukocyte profile assays using
the temporary RotaFlow CP and the now obsolete
VentrAssist implantable rotary blood pump. These
studies showed that hemolysis and leukocyte damage
do not necessarily correlate closely, and that a
pump with low hemolysis can still have a significant
damaging effect on leukocytes as shown for the
VentrAssist (9). With similar results using our
total blood damage profiling approach, both the
CentriMag and RotaFlow CP appear to be good
comparators when undertaking in vitro testing of
new implantable LVADs, although RotaFlow CP’s
effect on platelet activation would need to be estab-
lished first.
The field of in vitro blood damage profiling
remains at an early stage of development with a
need to address further aspects such as leukocyte
activation, origin of the leukocyte microparticles,
activation of the coagulation cascade, and the degra-
dation of vWF multimers. Recent results show that
increasing lactate dehydrogenase (LDH) levels can
be monitored as a possible predictor of pump
thrombosis in VAD patients (4). Developing a
greater understanding of other hemocompatibility
parameters such as changes in vWF, platelet, or leu-
kocyte activation, may provide even more sensitive
or early prediction of adverse reactions in clinical
trials of blood pumps.
CONCLUSIONS
In summary, we have demonstrated that the
CentriMag centrifugal blood pump has a low blood
damage profile during in vitro testing of bovine
FIG. 4. Platelet activation and apoptosis. Whole blood sampled
hourly from the pump circuit (CentriMag) or the control (static)
single-stained with BAQ125, CAPP2a, or Annexin V, and gated
as described in Supporting Information Fig. S2. Top: percentage
BAQ125- events; middle: percentage CAPP2a- events; and
bottom: percentage Annexin V+ events (n = 7, x ± SD). No sig-
nificant difference is observed between CentriMag and static
control during the 6 h tests.
FIG. 5. HMW vWF degradation. Platelet-poor plasma isolated
from blood sampled hourly from the pump circuit (CentriMag) or
the static control (n = 7) and analyzed by immunoblotting (top)
and densitometry of the blot (bottom). Bottom graph: time versus
rate of change in the gradient of HMW vWF. The level of the
HMW vWF multimers is significantly lower in the CentriMag com-
pared with the static control (P < 10−5) from around 3 h, and this
increases over time.
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blood. In our previous work, apart from the platelet
activation and vWF degradation assay, the RotaFlow
CP had similar low blood damage results compared
to the CentriMag CP. We therefore conclude that
these extracorporeal blood pumps, with their spa-
cious design and low shear stress, have an excellent
hemocompatibility profile and are good baseline con-
trols for in vitro testing of new implantable VADs.
Although bovine platelets were not activated in the
CentriMag, new evidence has shown that platelet
activation may be species-specific and device devel-
opers should validate results using several species
and/or human blood where possible.
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SUPPORTING INFORMATION
Additional Supporting Information may be found in
the online version of this article at the publisher’s
web-site:
Fig. S1. Leukocyte death gating strategy. Gating
steps 1–3: whole blood treated with Staurosporin to
induce leukocyte death was used to set up the gating
strategy for CD45-PE and 7AAD. (1) A leukocyte
gate was used to record 10 000 events. (2) Ungated
events on a CD45-PE vs SSC (log) dot plot identifies
CD45+ leukocytes. (3) CD45+ events on a 7AAD
versus SSC (log) dot plot distinguishes necrotic
7AAD+ events from 7AAD- healthy and frag-
mented leukocytes (MPs). Negative control: whole
untreated blood single-stained with CD45-PE.
Fig. S2. Platelet activation and apoptosis gating
strategy. (A) Ungated events displayed on FSC
versus SSC on logarithmic axes. Platelets were gated
and 10 000 events recorded. (B and C) Ungated
population displayed on a histogram of BAQ125-
PE (B) or CAPP2a-PE (C) intensity and activated
platelets (negative events) were gated. (D) Platelet
population displayed on a histogram of Annexin
V-eFluor450 intensity and Annexin V-positive
(apoptotic) platelets were gated.
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